Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • apixaban

    - PMLiVE

    Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

    Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

    - PMLiVE

    Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

    The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

    - PMLiVE

    BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

    Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

    - PMLiVE

    BMS receives FDA approval for immunotherapy combination in liver cancer

    Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

    - PMLiVE

    BMS granted FDA approval for immunotherapy combination in colorectal cancer

    More than 154,000 cases of the disease are expected to be diagnosed in the US this year

    - PMLiVE

    BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

    Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

    - PMLiVE

    BMS granted EC approval for immunotherapy combination in liver cancer

    More than 866,100 cases of the disease were diagnosed globally in 2022

    - PMLiVE

    BMS shares overall survival results for Opdivo in phase 3 lung cancer trial

    More than 200,000 people are diagnosed with lung cancer in the US every year

    - PMLiVE

    BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

    Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally

    - PMLiVE

    BMS presents promising data for immunotherapy combination in phase 3 colorectal cancer trial

    Over 154,000 cases of colorectal cancer are expected to be diagnosed in the US in 2025

    - PMLiVE

    Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval

    Opdivo Qvantig can be administered in three to five minutes compared to 30 minutes for the drug’s IV form

    - PMLiVE

    Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell engager

    The candidate targets a tumour antigen that is highly expressed across several cancer types

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links